tetano
Editor, Senior Moderator
Viruses
. 2022 May 15;14(5):1049.
doi: 10.3390/v14051049.
Development of DNA Vaccine Candidate against SARS-CoV-2
Xingyun Wang[SUP] 1 [/SUP], Nino Rcheulishvili[SUP] 1 [/SUP], Jie Cai[SUP] 1 [/SUP], Cong Liu[SUP] 1 [/SUP], Fengfei Xie[SUP] 1 [/SUP], Xing Hu[SUP] 1 [/SUP], Nuo Yang[SUP] 1 [/SUP], Mengqi Hou[SUP] 1 [/SUP], Dimitri Papukashvili[SUP] 1 [/SUP], Yunjiao He[SUP] 1 [/SUP], Peng George Wang[SUP] 1 [/SUP]
Affiliations
Abstract
Despite the existence of various types of vaccines and the involvement of the world's leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies.
Keywords: COVID-19; DNA vaccine; SARS-CoV-2.
. 2022 May 15;14(5):1049.
doi: 10.3390/v14051049.
Development of DNA Vaccine Candidate against SARS-CoV-2
Xingyun Wang[SUP] 1 [/SUP], Nino Rcheulishvili[SUP] 1 [/SUP], Jie Cai[SUP] 1 [/SUP], Cong Liu[SUP] 1 [/SUP], Fengfei Xie[SUP] 1 [/SUP], Xing Hu[SUP] 1 [/SUP], Nuo Yang[SUP] 1 [/SUP], Mengqi Hou[SUP] 1 [/SUP], Dimitri Papukashvili[SUP] 1 [/SUP], Yunjiao He[SUP] 1 [/SUP], Peng George Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 35632789
- DOI: 10.3390/v14051049
Abstract
Despite the existence of various types of vaccines and the involvement of the world's leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies.
Keywords: COVID-19; DNA vaccine; SARS-CoV-2.